ranibizumabafliberceptfaricimabBrolucizumab
…tients (10 injections); faricimab 94 patients (321 injections); ranibizumab 37 patients (127 injections).Classified by most frequent diagno…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 20 of 2459nivolumabnon-small cell lung cancerpembrolizumabpemetrexedmelanomaFDA
…ted 76 164 life years gained. Only three accelerated approvals (nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…
Diabetestype 2 diabetesPharmacotherapiestransient ischemic attackgestational diabetespharmacotherapymyocardial infarctionstrokeWorld Bank
…nd fragmented care delivery. As emphasized in the 2025 American Diabetes Association Standards of Care, episodic clinical visits alone a…
Rheumatoid Arthritisankylosing spondylitisPsoriasisosteoporosisbenralizumabadalimumabmepolizumabinflammatory bowel disease
… Denosumab Osteoporosis 44 Nil Yes No 5 Benralizumab Adalimumab Rheumatoid Arthritis 24 Nil Yes No Benralizumab Adalimumab Ankylosing Spondylitis 5 …
Balt GroupSilk Road MedicalTRUFILL n-BCANational Center for Advancing Translational SciencesMiami Clinical and Translational Science InstitutecSDHMedtronicIntegra LifeSciencesTRUFILL n-Butyl Cyanoacrylatechronic subdural hematomas (cSDH)+2 more
…estricted research, Medtronic (unrestricted research grant) and Balt Group (unrestricted research grant). F. Al-Mufti: 2; C; Stryker Neuro…
ustekinumabvedolizumab
…ad documented clinical response or remission after switching to ustekinumab. 2 patients not responding subsequently switched from ustekinum…
DobutamineDobutamine-stressAspirin24adenosineadenosine-stress
… sensitivity, but lower specificity than adenosine-stress CMRD. Dobutamine- and adenosine-stress CMR showed comparable sensitivity, specif…
VPM1002Immuvacextrapulmonary TB
…gainst extrapulmonary TB in participants aged 6-14 years in the VPM1002 group.Conclusions Both vaccines were safe but did not show any …
NHS Englandcovid-19inflammatory skin diseaseadvice and guidanceNHS
…m factors that influence decision making about mode of referral.NHS England instructed trusts in 2020 to disaggregate waiting lists by ethn…
TIGIT inhibitorsEtigilimabNational Cancer InstitutecancerRilvegostomigTIGIT inhibitorPD1 inhibitorDargistotugacademic centres
…clinical trials of TIGIT inhibitors should be questioned. Seven TIGIT inhibitors (all Fc-enabled) did not recapitulate in clinical trials the pr…
Adaptimmunelete-celsynovial sarcomaSySMRCLS
…nced SyS and MRCLS.Acknowledgements This analysis was funded by Adaptimmune. Writing and editorial support was by Chloe Koulouris, PhD, of …